New Jersey’s Attorney General and Division of Consumer Affairs alerted the public that three synthetic kratom-related compounds became illegal to possess or sell in the state under a temporary federal scheduling order. The release describes a controlled-substance alert, not a privacy enforcement action, and identifies no company, privacy violation, or monetary penalty.
No privacy-related remedy or monetary penalty is described. The alert states that the listed compounds are scheduled as illegal to possess or sell in New Jersey, with potential criminal charges for violations.
This release does not describe a privacy enforcement action, so it does not indicate a need to revise privacy or data-processing clauses. Product, procurement, and legal teams dealing in kratom-related products should review supplier and distribution agreements for representations that products and ingredients comply with applicable controlled-substance laws, ingredient and labeling disclosure obligations, prompt notice of regulatory changes, audit or documentation rights, and rights to suspend sales or terminate if an ingredient becomes restricted. Customer-facing terms may also need review for accurate product descriptions and restrictions on sale or possession.
Entity
Mitragynine pseudoindoxyl, MGM-15, and MGM-16
Industry
OtherOfficial Press Release
https://www.njoag.gov/ag-davenport-division-of-consumer-affairs-issue-public-alert-three-types-of-synthetic-kratom-to-be-listed-as-controlled-dangerous-substances-in-new-jersey/
New Jersey Attorney General Enforcement Page
https://www.njoag.gov/about/divisions-and-offices/division-of-consumer-affairs/
"mitragynine pseudoindoxyl, MGM-15, and MGM-16"
"Under New Jersey law, if the federal government schedules a drug and the Director of the Division of Consumer Affairs does not object–which he did not in this case– that drug automatically becomes scheduled in New Jersey too."
"In August 2026, the U.S. Drug Enforcement Administration (DEA) temporarily classified three synthetic compounds related to synthetic kratom–mitragynine pseudoindoxyl, MGM-15, and MGM-16–as Schedule I drugs."
"Starting Today, Anyone Possessing or Selling These Products Could Face Criminal Charges"
"For Immediate Release: September 25, 2026"
$2.3M
Laboratory Corporation of America Holdings agreed to pay $2,287,455 to participating states and strengthen its security and vendor-management practices following an investigation into the 2019 breach at its debt-collection vendor, AMCA. The breach potentially exposed information of more than 27.5 million people nationwide, including sensitive information belonging to approximately 10.2 million LabCorp patients.
$694.0M
New Jersey's Attorney General and Division of Consumer Affairs, along with 41 Attorneys General, reached a $694 million settlement with subprime auto lender Credit Acceptance Corporation over allegations it originated unaffordable loans its own systems predicted borrowers could not repay, employed aggressive debt-collection tactics, and failed to prevent deceptive vehicle-service contract and GAP product 'packing' by dealers. The multistate settlement stepped in after the CFPB permanently dropped its 2023 enforcement action against CAC in 2025. CAC will provide $60 million in cash restitution, $634 million in debt relief, an additional $15 million to the states, and implement injunctive lending reforms including loan off ramps, pre-loan disclosures, add-on packing safeguards, and a seven-year vehicle price cap. Note: this is a consumer-protection lending enforcement action, not a privacy matter; violation categories are best-fit mappings from the available taxonomy.
$650K
The New Jersey Attorney General and Division of Consumer Affairs announced that Match Group, Inc. will pay $650,000 and change its business practices to settle allegations that it misrepresented or failed to disclose its criminal background screening policies and practices to New Jersey users, violating the New Jersey Consumer Fraud Act and the Internet Dating Safety Act. Under a Consent Order, Match must accurately represent its screening policies, notify existing New Jersey members of updated disclosures within 150 days, and post clear and conspicuous disclosures and safety notifications about the limitations of criminal background screenings.
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
On August 31, 2026, New Jersey Attorney General Jennifer Davenport and the Division of Consumer Affairs joined the FTC and a bipartisan coalition of 21 other states in suing Amazon, alleging that for over seven years the company secretly rigged its advertising auctions—converting advertised 'second price' auctions into first-price auctions with hidden 'soft reserve price' surcharges—overcharging more than 500,000 small- and medium-sized businesses and extracting tens of billions of dollars. The complaint alleges Amazon actively concealed the surcharges, gave false and misleading answers to advertisers who asked directly about the auction format, and applied inflated upcharges on high-volume shopping days like Prime Day and Black Friday. The lawsuit was just filed; no penalties or remedies have been imposed yet.
A bipartisan coalition of state attorneys general led by New Jersey, California, Colorado, and Kentucky is taking Meta Platforms, Inc. to trial, alleging that Meta designed addictive features on Instagram and Facebook that harm minors' mental health, illegally collected data from children under 13 without the required protections under COPPA, and misled users about platform safety. Opening arguments begin August 18, 2026, in the U.S. District Court for the Northern District of California. No monetary penalty or final remedy has yet been imposed.